Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges.LEVEL OF EVIDENCE: Level V, descriptive studies.PMID:38015342 | PMC:PMC10684642 | DOI:10.1007/s40519-023-01625-5
Source: Eating and weight disorders : EWD - Category: Eating Disorders & Weight Management Authors: Silvia Tempia Valenta Michele Stecchi Federica Perazza Chiara Nuccitelli Nicola Villanova Loris Pironi Anna Rita Atti Maria Letizia Petroni Source Type: research
More News: Anxiety | Binge Eating Disorder | Depression | Eating Disorders & Weight Management | Men | Obesity | Psychiatry | Study | Victoza | Weight Loss